Vannini Alessandro, Volpari Cinzia, Filocamo Gessica, Casavola Elena Caroli, Brunetti Mirko, Renzoni Debora, Chakravarty Prasun, Paolini Chantal, De Francesco Raffaele, Gallinari Paola, Steinkühler Christian, Di Marco Stefania
Department of Biochemistry, Istituto di Ricerche di Biologia Molecolare P. Angeletti, 00040 Pomezia, Rome, Italy.
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15064-9. doi: 10.1073/pnas.0404603101. Epub 2004 Oct 11.
Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of gene expression, DNA repair, and stress response. These processes often are altered in tumors, and HDAC inhibitors have had pronounced antitumor activity with promising results in clinical trials. Here, we report the crystal structure of human HDAC8 in complex with a hydroxamic acid inhibitor. Such a structure of a eukaryotic zinc-dependent HDAC has not be described previously. Similar to bacterial HDAC-like protein, HDAC8 folds in a single alpha/beta domain. The inhibitor and the zinc-binding sites are similar in both proteins. However, significant differences are observed in the length and structure of the loops surrounding the active site, including the presence of two potassium ions in HDAC8 structure, one of which interacts with key catalytic residues. CD data suggest a direct role of potassium in the fold stabilization of HDAC8. Knockdown of HDAC8 by RNA interference inhibits growth of human lung, colon, and cervical cancer cell lines, highlighting the importance of this HDAC subtype for tumor cell proliferation. Our findings open the way for the design and development of selective inhibitors of HDAC8 as possible antitumor agents.
组蛋白去乙酰化酶(HDACs)是一类参与基因表达调控、DNA修复和应激反应的酶。这些过程在肿瘤中常常发生改变,HDAC抑制剂具有显著的抗肿瘤活性,在临床试验中取得了令人鼓舞的结果。在此,我们报道了人HDAC8与一种异羟肟酸抑制剂复合物的晶体结构。此前尚未描述过这种真核生物锌依赖性HDAC的结构。与细菌类HDAC蛋白相似,HDAC8折叠成一个单一的α/β结构域。两种蛋白质中的抑制剂和锌结合位点相似。然而,在活性位点周围环的长度和结构上观察到显著差异,包括HDAC8结构中有两个钾离子,其中一个与关键催化残基相互作用。圆二色性数据表明钾在HDAC8的折叠稳定性中起直接作用。通过RNA干扰敲低HDAC8可抑制人肺癌、结肠癌和宫颈癌细胞系的生长,突出了这种HDAC亚型对肿瘤细胞增殖的重要性。我们的发现为设计和开发作为可能抗肿瘤药物选择性HDAC8抑制剂开辟了道路。